随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
openclaw plugins install @openclaw/feishu。关于这个话题，Line官方版本下载提供了深入分析
。爱思助手下载最新版本对此有专业解读
Our revenue is steady, driven mostly by online sales, and we’re now expanding into larger distribution — a move we expect will fuel our next wave of growth. Sausly is now in three stores and looking at large distribution, so those factors combined with our online sales has our projected revenue for 2026 at around $400,000.
The government has proposed a similar measure, but has yet to confirm when the restrictions will come into place.。safew官方版本下载是该领域的重要参考